Hoffmann-la Roche Inc.

Unversität Zürich

Eidgenössische Technische Hochschule Zürcih

F. Hoffmann-la Roche Ag

Eidgenossische Technische Hochschule Zurich

Juergen Fingerle

Mark Rogers-Evans

Uwe Grether

Luca Claudio Gobbi

Ulrich Kohnert

Simon Mensah Ametamey

Christoph Ullmer

Monika Baehner

Martin Bader

Thomas Hartung

Ahmed Haider

Linjing Mu

Leo Nicholls

Jean-Luc Mary

Silke Mohl

The present invention relates to a compound of formula (I) wherein Ris defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

Radiolabeled cannabinoid receptor 2 ligand

A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one embodiment the lipid is a second phosphatidylcholine, wherein the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the apolipoprotein is selected from an apolipoprotein that has the amino acid sequence selected from SEQ ID NO: 01, 02, 06, 66, and 67, or is a variant thereof that has at least 70% sequence identity with the selected sequence.

Tetranectin-apolipoprotein A-I, lipid particles containing it and its use

Growing community of inventors

Kandern, Germany

Juergen Fingerle